US Patent

US9682061 — Methods of treating bacterial infections using oritavancin

Method of Use · Assigned to Medicines Co · Expires 2030-04-26 · 4y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods of treating bacterial infections in a subject using a therapeutically effective amount of oritavancin.

USPTO Abstract

The present invention is directed to methods of treating a bacterial infection in a subject through the administration of a therapeutically effective amount of a glycopeptide antibiotic to a subject having a bacterial infection. The effective amount of the glycopeptide antibiotic that is administered to the subject provides a fraction of the glycopeptide antibiotic administered to the subject bound to serum proteins within the subject and within a selected range.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1569 oritavancin-diphosphate
U-3101 oritavancin-diphosphate

Patent Metadata

Patent number
US9682061
Jurisdiction
US
Classification
Method of Use
Expires
2030-04-26
Drug substance claim
No
Drug product claim
No
Assignee
Medicines Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.